Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CTL-119 by Novartis for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
CTL-119 is under clinical development by Novartis and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
CTL-119 by Novartis for Non-Hodgkin Lymphoma: Likelihood of Approval
CTL-119 is under clinical development by Novartis and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...
CTL-119 by Novartis for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
CTL-119 is under clinical development by Novartis and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...